Beijing Luzhu Biotech Listing on HKEX；Patrons Serves as the Bookrunner

Established in 2001, Beijing Luzhu Biotechnology ("Luzhu Biotech") is one of the earliest biotechnology companies in China. With human vaccines and therapeutic antibodies as its main research direction, it is dedicated to providing high quality and affordable human vaccines and therapeutic biologics. Since its establishment in 2001, the company has built up an innovative technology platform through its deep understanding of immunology and protein engineering, and has achieved outstanding success in the field of human medicine.

Patrons has cooperated sincerely with Luzhu Biotech, relying on our top-notch team and resources in Mainland China and Hong Kong in order to provide the high quality development for our customers. The listing of Luzhu Biotech on the Hong Kong Stock Exchange is another typical case of the IPO counseling project of Patrons.

On 8 May 2023, Luzhu Biotech was successfully listed on the Hong Kong Stock Exchange with Patrons serving as the bookrunner. Luzhu Biotech shares were issued under stock code (02480.HK) at an issue price of HK$32.80 per H share.